75 Improving the functional status of patients with cancer by more effectively preventing chemotherapy-induced nausea and vomiting (CINV): results of a phase 3 study of NEPA (fixed-dose combination of netupitant and palonosetron)

European Journal of Oncology Nursing ◽

10.1016/s1462-3889(14)70093-6 ◽

2014 ◽

Vol 18 ◽

pp. S20-S21 ◽

Cited By ~ 4

Author(s):

P. Jahn ◽

K. Jordan ◽

G. Rizzi

Keyword(s):

Functional Status ◽

Nausea And Vomiting ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Phase 3 ◽

Patients With Cancer ◽

Dose Combination

Download Full-text

Phase 3 study of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting during repeated moderately emetogenic chemotherapy (MEC) cycles.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.9502 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 9502-9502 ◽

Cited By ~ 4

Author(s):

Matti S. Aapro ◽

Meinolf Karthaus ◽

Lee Steven Schwartzberg ◽

Giorgia Rossi ◽

Giada Rizzi ◽

...

Keyword(s):

Emetogenic Chemotherapy ◽

Nausea And Vomiting ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Moderately Emetogenic Chemotherapy ◽

Phase 3 ◽

Dose Combination

Download Full-text

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

10.26226/morressier.5aeaf2d35800a00019097f85 ◽

2018 ◽

Author(s):

Christian Wisskirchen ◽

Hans-Jürgen Stellbrink

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination ◽

Hiv 1

Download Full-text

Faculty Opinions recommendation of Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725431366.793505980 ◽

2015 ◽

Author(s):

Philip Rosenthal

Keyword(s):

Hepatitis C ◽

Japanese Patients ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Open Label ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination ◽

Previously Treated

Download Full-text

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting

Journal of the Advanced Practitioner in Oncology ◽

10.6004/jadpro.2016.7.1.5 ◽

2016 ◽

Vol 7 (1) ◽

Author(s):

Joseph W. Coyne, RPh

Keyword(s):

Nausea And Vomiting ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Dose Combination

Download Full-text

Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2

Advances in Therapy ◽

10.1007/s12325-020-01277-2 ◽

2020 ◽

Vol 37 (4) ◽

pp. 1620-1631 ◽

Cited By ~ 4

Author(s):

Sanjay Asrani ◽

Jason Bacharach ◽

Edward Holland ◽

Hayley McKee ◽

Huan Sheng ◽

...

Keyword(s):

Ocular Hypertension ◽

Open Angle Glaucoma ◽

Safety Analysis ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Open Angle ◽

Phase 3 ◽

Dose Combination

Download Full-text

Prevention of Chemotherapy-Induced Nausea and Vomiting with a Fixed-Dose Combination of Netupitant and Palonosetron (Nepa) Following Highly Emetogenic Chemotherapy: Evaluation of Response Based on Gender and Age

Annals of Oncology ◽

10.1093/annonc/mdu356.9 ◽

2014 ◽

Vol 25 ◽

pp. iv520 ◽

Cited By ~ 1

Author(s):

P. Hesketh ◽

K. Jordan ◽

R. Gralla

Keyword(s):

Emetogenic Chemotherapy ◽

Nausea And Vomiting ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Highly Emetogenic Chemotherapy ◽

Gender And Age ◽

Dose Combination

Download Full-text

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

Journal of Hepatology ◽

10.1016/s0168-8278(14)60111-2 ◽

2014 ◽

Vol 60 (1) ◽

pp. S45 ◽

Cited By ~ 1

Author(s):

N. Afdhal ◽

R.K. Reddy ◽

P. Pockros ◽

A.M. Di Bisceglie ◽

S. Arora ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Phase 3 ◽

Dose Combination

Download Full-text

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

Gastroenterology ◽

10.1016/s0016-5085(14)63284-4 ◽

2014 ◽

Vol 146 (5) ◽

pp. S-903 ◽

Cited By ~ 1

Author(s):

Ira M. Jacobson ◽

Patrick Marcellin ◽

Alessandra Mangia ◽

Paul Y. Kwo ◽

Graham Foster ◽

...

Keyword(s):

Fixed Dose Combination ◽

Fixed Dose ◽

Genotype 1 ◽

Phase 3 ◽

Treatment Naïve ◽

Dose Combination

Download Full-text

A phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naïve adults at week 48

10.26226/morressier.5aeaf2d35800a00019097f7f ◽

2018 ◽

Author(s):

Jürgen K. Rockstroh ◽

Christian Wisskirchen

Keyword(s):

Clinical Trial ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Controlled Clinical Trial ◽

Randomized Controlled Clinical Trial ◽

Phase 3 ◽

Randomized Controlled ◽

Treatment Naïve ◽

Dose Combination

Download Full-text

Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron

10.1158/0008-5472.sabcs13-p3-09-01 ◽

2013 ◽

Cited By ~ 2

Author(s):

HS Rugo ◽

G Rossi ◽

G Rizzi ◽

ME Borroni ◽

V Lorusso ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Daily Living ◽

Nausea And Vomiting ◽

Fixed Dose Combination ◽

Fixed Dose ◽

Breast Cancer Patients ◽

Dose Combination ◽

The Impact

Download Full-text